The safety of the new vaccines against SARS-CoV-2 have already been shown, although data on patients with polyneuropathy are still lacking. The aim of this study is to evaluate the adherence to SARS-CoV-2 vaccination, as well as the reactogenicity to those vaccines in patients affected by neuropathy.
Adherence and Reactogenicity to Vaccines against SARS-COV-2 in 285 Patients with Neuropathy: A Multicentric Study / Iacono, S., Di Stefano, V., Alonge, P., Vinciguerra, C., Milella, G., Caputo, F., Lasorella, P., Neto, G., Pignolo, A., Torrente, A., Lupica, A., Ajdinaj, P., Firenze, A., Tozza, S., Manganelli, F., Di Muzio, A., Piscosquito, G., Brighina, F.. - In: BRAIN SCIENCES. - ISSN 2076-3425. - 12:10(2022), p. 1396. [10.3390/brainsci12101396]
Adherence and Reactogenicity to Vaccines against SARS-COV-2 in 285 Patients with Neuropathy: A Multicentric Study
Tozza, Stefano;Manganelli, Fiore;
2022
Abstract
The safety of the new vaccines against SARS-CoV-2 have already been shown, although data on patients with polyneuropathy are still lacking. The aim of this study is to evaluate the adherence to SARS-CoV-2 vaccination, as well as the reactogenicity to those vaccines in patients affected by neuropathy.| File | Dimensione | Formato | |
|---|---|---|---|
|
brainsci-12-01396.pdf
accesso aperto
Licenza:
Copyright dell'editore
Dimensione
1.72 MB
Formato
Adobe PDF
|
1.72 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
